03.07.2015 • NewsDede WillamsLonzaAlexion

Lonza Signs New Agreement with Alexion

Lonza has signed a new long-term product supply agreement with compatriot Alexion Pharmaceuticals.

Under the terms of the contract, an expansion of an existing manufacturing agreement, the Swiss life sciences group will build, own and operate a new toll manufacturing suite for the drugmaker beginning in 2017 at its Portsmouth, New Hampshire site in the US.

The new agreement will supplement existing production of Alexion products at multiple Lonza facilities and will enable Alexion to add dedicated product supply for 10 years.

Lonza said the expansion will allow customers increased access to its proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. The company can look back on more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.